Ascend Wellness Holdings (AAWH) Cost of Revenue (2020 - 2026)
Ascend Wellness Holdings' (AAWH) quarterly Cost of Revenue came in at $72.1 million in Q1 2026, down 18.53% year-on-year from $88.4 million in Q1 2025, and down 4.47% quarter-over-quarter from $75.4 million in Q4 2025.
Ascend Wellness Holdings (AAWH) Cost of Revenue (2020 - 2026) Analysis & Trends
Ascend Wellness Holdings' Cost of Revenue history runs 7 years deep, the most recent figure standing at $72.1 million for Q1 2026.
- On a quarterly basis, Cost of Revenue fell 18.53% year-over-year to $72.1 million in Q1 2026; TTM through Mar 2026 was $314.5 million, a 16.23% decrease from a year earlier, with the FY2025 full-year figure at $330.9 million, down 12.32% from the prior year.
- Cost of Revenue declined to $72.1 million in Q1 2026 per AAWH's latest filing, from $75.4 million in the prior quarter.
- Across five years, Cost of Revenue topped out at $100.0 million in Q2 2024 and bottomed at $61.6 million in Q1 2022.
- The 5-year median for Cost of Revenue is $85.9 million (2025), against an average of $83.2 million.
- Across the five-year window, Cost of Revenue soared 69.02% in 2022 and decreased 18.53% in 2026, its largest moves.
- Year by year, Cost of Revenue stood at $70.6 million in 2022, then jumped by 31.21% to $92.6 million in 2023, then decreased by 3.76% to $89.1 million in 2024, then fell by 15.39% to $75.4 million in 2025, then fell by 4.47% to $72.1 million in 2026.
- Per Business Quant, the three latest AAWH Cost of Revenue figures stand at $72.1 million (Q1 2026), $75.4 million (Q4 2025), and $81.1 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 2.01 Bn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 641.00 Mn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 2.59 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 133.40 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 2.36 Bn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 13.80 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 586.00 Mn |
| 10 | Ascend Wellness Holdings | 78.95 Mn | 18.03 Mn | 44.88 Mn | 72.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 72.05 Mn |
| Mar 31, 2026 | 72.05 Mn |
| Dec 31, 2025 | 75.42 Mn |
| Dec 31, 2025 | 75.42 Mn |
| Sep 30, 2025 | 81.13 Mn |
| Sep 30, 2025 | 81.13 Mn |
| Jun 30, 2025 | 85.91 Mn |
| Jun 30, 2025 | 85.91 Mn |
| Mar 31, 2025 | 88.44 Mn |
| Mar 31, 2025 | 88.44 Mn |
| Dec 31, 2024 | 89.14 Mn |
| Dec 31, 2024 | 89.14 Mn |
| Sep 30, 2024 | 97.92 Mn |
| Sep 30, 2024 | 97.92 Mn |
| Jun 30, 2024 | 99.96 Mn |
| Jun 30, 2024 | 99.96 Mn |
| Mar 31, 2024 | 90.37 Mn |
| Mar 31, 2024 | 90.37 Mn |
| Dec 31, 2023 | 92.62 Mn |
| Dec 31, 2023 | 92.62 Mn |